For Referring Providers

The following information is for referring providers only.

Use of oral therapy with nirmatrelvir with ritonavir (Paxlovid) is preferred when no contraindications are present. Providers can initiate a request for treatment infusions for ambulatory patients with mild to moderate COVID-19 by completing the site-specific referral form in the Alternatives to Paxlovid section below. Referrals will be reviewed as rapidly as possible.

Alternatives to Nirmatrelvir with Ritonavir (Paxlovid)

For patients who are unable to receive nirmatrelvir with ritonavir (Paxlovid) due to intractable medication interactions or other contraindications, remdesivir is available at BIDMC. Molnupiravir is another oral option for mild-moderate COVID-19 for carefully selected ambulatory patients unable to take nirmatrelvir/ritonavir (Paxlovid) or receive remdesivir.

Beth Israel Deaconess Medical Center

All providers, including BILH and non-BILH providers:

  • Complete a BIDMC COVID-19 Therapeutics Referral Form and email the Form here or fax to 617-754-8861.
  • Patients must have a BILH Epic MRN to process their referral request. If they do not have one, please have them call 617-754-8240 to register.
  • All patients referred using the Referral Form will require a telehealth consultation with a BIDMC COVID-19 Therapeutics team provider before scheduling treatment.

BIDMC providers with Epic access may use Epic to refer patients in lieu of the Referral Form process:

  • Enter the “BILH Remdesivir 3-day Infusion” under therapy plans, and select “BIDMC FA3 COVID infusion” as the ordering location. Include a note in Epic with the symptom/test date and qualifying risk factor(s).
  • If “BILH Remdesivir 3-day Infusion” therapy plans is not available to you in Epic, please use the BIDMC COVID-19 Therapeutics Referral Form process as outlined above.
General Information
  • All referrals and submissions for treatment are reviewed daily (Monday through Friday) by the BIDMC COVID-19 treatment team.
  • Intravenous outpatient COVID-19 therapy is available Monday through Saturday (excluding holidays) and is subject to availability.
  • Patients remain eligible for treatment up to 7 days from symptom onset. If a treatment slot is assigned, the COVID-19 ambulatory treatment team will contact the patient directly to schedule.
  • For all questions, please email covidmab@bidmc.harvard.edu.